https://www.selleckchem.com/pr....oducts/ldc203974-imt
These data represent the first proof of concept for a therapy to treat patients with NMNAT1-associated disease.Chimeric antigen receptor (CAR) T cells targeting CD123, an acute myeloid leukemia (AML) antigen, hold the promise of improving outcomes for patients with refractory/recurrent disease. We generated five lentiviral vectors encoding CD20, which may serve as a target for CAR T cell depletion, and 2nd or 3rd generation CD123-CARs since the benefit of two costimulatory domains is model dependent. Four CARs were based on the
Like
Comment
Share
